Bank of N.T. Butterfield & Son (CVE:NTB) Price Target & New Coverage by Goldman Sachs
Goldman Sachs initiated its coverage on Bank of N.T. Butterfield & Son (CVE:NTB), today Tuesday morning. The firm finds the stock of NTB attractive and has target price per share of $27.0 with “Neutral” rating.
Despite the new coverage CVE:NTB is currently trading 0.00% lower at $0.00 as of 04:04 New York time. Bank of N.T. Butterfield & Son shares have risen 35.25% in the past 200 days, while the S&P500 Index has increased 4.81% for the same time period.
CVE:NTB Price Chart & Trend
The stock price of Bank of N.T. Butterfield & Son gained 35.25% over the last 200 days, and is in very strong up trend. In the last 50 and 100 days, Bank of N.T. Butterfield & Son is up 33.33% and up 38.24%, respectively. Our stocks momentum model is shown on the price chart below.
Bank of N.T. Butterfield & Son (CVE:NTB) Profile
Neptune Technologies & Bioressources Inc. is a solution provider of omega-3’s and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company’s products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti.
Bank of N.T. Butterfield & Son (CVE:NTB) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of 31,215 shares. Bank of N.T. Butterfield & Son has a 52 week low of $2.01 and a 52 week high of $4.46. The company has a market cap of $147.24 million and a P/E ratio of 0.
Get the latest Bank of N.T. Butterfield & Son (CVE:NTB) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Bank of N.T. Butterfield & Son - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.